Cargando…
Clinical Phenotypes of COVID-19 Associated Mucormycosis (CAM): A Comprehensive Review
A mucormycosis surge was reported during the COVID-19 pandemic in India. A literature search until 14 July 2022, with the aim of updating COVID-19-associated mucormycosis (CAM), identified 663 studies and 88 met inclusion criteria (8727 patients). India reported 8388 patients, Egypt 208 and Europe 4...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9777018/ https://www.ncbi.nlm.nih.gov/pubmed/36553099 http://dx.doi.org/10.3390/diagnostics12123092 |
_version_ | 1784856001412857856 |
---|---|
author | Almyroudi, Maria Panagiota Akinosoglou, Karolina Rello, Jordi Blot, Stijn Dimopoulos, George |
author_facet | Almyroudi, Maria Panagiota Akinosoglou, Karolina Rello, Jordi Blot, Stijn Dimopoulos, George |
author_sort | Almyroudi, Maria Panagiota |
collection | PubMed |
description | A mucormycosis surge was reported during the COVID-19 pandemic in India. A literature search until 14 July 2022, with the aim of updating COVID-19-associated mucormycosis (CAM), identified 663 studies and 88 met inclusion criteria (8727 patients). India reported 8388 patients, Egypt 208 and Europe 40. Rhino-orbito-cerebral mucormycosis (ROCM) was identified among 8082 (98.3%) patients, followed by 98 (1.2%) with pulmonary. In India, 82.6% of patients had diabetes mellitus, with 82% receiving corticosteroids. In Europe, 75% presented pulmonary CAM, 32.5% had diabetes and 40% were immunocompromised. CAM was identified at a median of 17.4 days (IQR 7.5 days) post COVID-19 diagnosis, and PCR was performed in five studies. Rhino-orbital invasion is clinically obvious, while cerebral involvement presents with cavernous sinus thrombosis, meningitis and cerebrovascular disease. Symptoms of pulmonary CAM usually overlap with severe COVID-19 pneumonia. High-dose liposomal Amphotericin B (and early surgical debridement in ROCM) are the mainstay of therapy. The median mortality rate was estimated to be 21.4% (IQR 31.9%), increased by the presence of pulmonary (80% (IQR 50%) or cerebral involvement (50% (IQR 63.9%). In summary, different CAM clinical phenotypes need to be distinguished, influenced by geographical presentation. Opportunities exist for diagnosis and therapy optimization, based on earlier high-dose antifungal therapy, early source control, strict glycemic control and restriction of steroids to COVID-19 patients with oxygen requirements. |
format | Online Article Text |
id | pubmed-9777018 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-97770182022-12-23 Clinical Phenotypes of COVID-19 Associated Mucormycosis (CAM): A Comprehensive Review Almyroudi, Maria Panagiota Akinosoglou, Karolina Rello, Jordi Blot, Stijn Dimopoulos, George Diagnostics (Basel) Review A mucormycosis surge was reported during the COVID-19 pandemic in India. A literature search until 14 July 2022, with the aim of updating COVID-19-associated mucormycosis (CAM), identified 663 studies and 88 met inclusion criteria (8727 patients). India reported 8388 patients, Egypt 208 and Europe 40. Rhino-orbito-cerebral mucormycosis (ROCM) was identified among 8082 (98.3%) patients, followed by 98 (1.2%) with pulmonary. In India, 82.6% of patients had diabetes mellitus, with 82% receiving corticosteroids. In Europe, 75% presented pulmonary CAM, 32.5% had diabetes and 40% were immunocompromised. CAM was identified at a median of 17.4 days (IQR 7.5 days) post COVID-19 diagnosis, and PCR was performed in five studies. Rhino-orbital invasion is clinically obvious, while cerebral involvement presents with cavernous sinus thrombosis, meningitis and cerebrovascular disease. Symptoms of pulmonary CAM usually overlap with severe COVID-19 pneumonia. High-dose liposomal Amphotericin B (and early surgical debridement in ROCM) are the mainstay of therapy. The median mortality rate was estimated to be 21.4% (IQR 31.9%), increased by the presence of pulmonary (80% (IQR 50%) or cerebral involvement (50% (IQR 63.9%). In summary, different CAM clinical phenotypes need to be distinguished, influenced by geographical presentation. Opportunities exist for diagnosis and therapy optimization, based on earlier high-dose antifungal therapy, early source control, strict glycemic control and restriction of steroids to COVID-19 patients with oxygen requirements. MDPI 2022-12-08 /pmc/articles/PMC9777018/ /pubmed/36553099 http://dx.doi.org/10.3390/diagnostics12123092 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Almyroudi, Maria Panagiota Akinosoglou, Karolina Rello, Jordi Blot, Stijn Dimopoulos, George Clinical Phenotypes of COVID-19 Associated Mucormycosis (CAM): A Comprehensive Review |
title | Clinical Phenotypes of COVID-19 Associated Mucormycosis (CAM): A Comprehensive Review |
title_full | Clinical Phenotypes of COVID-19 Associated Mucormycosis (CAM): A Comprehensive Review |
title_fullStr | Clinical Phenotypes of COVID-19 Associated Mucormycosis (CAM): A Comprehensive Review |
title_full_unstemmed | Clinical Phenotypes of COVID-19 Associated Mucormycosis (CAM): A Comprehensive Review |
title_short | Clinical Phenotypes of COVID-19 Associated Mucormycosis (CAM): A Comprehensive Review |
title_sort | clinical phenotypes of covid-19 associated mucormycosis (cam): a comprehensive review |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9777018/ https://www.ncbi.nlm.nih.gov/pubmed/36553099 http://dx.doi.org/10.3390/diagnostics12123092 |
work_keys_str_mv | AT almyroudimariapanagiota clinicalphenotypesofcovid19associatedmucormycosiscamacomprehensivereview AT akinosogloukarolina clinicalphenotypesofcovid19associatedmucormycosiscamacomprehensivereview AT rellojordi clinicalphenotypesofcovid19associatedmucormycosiscamacomprehensivereview AT blotstijn clinicalphenotypesofcovid19associatedmucormycosiscamacomprehensivereview AT dimopoulosgeorge clinicalphenotypesofcovid19associatedmucormycosiscamacomprehensivereview |